We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Allergy Therapeutics Plc (AGY) Ord GBP0.01

Sell:5.00p Buy:5.50p 0 Change: 0.1p (1.92%)
Market closed Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.00p
Buy:5.50p
Change: 0.1p (1.92%)
Market closed Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:5.00p
Buy:5.50p
Change: 0.1p (1.92%)
Market closed Prices as at close on 22 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil, Oralvac and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

Contact details

Address:
Dominion Way
WORTHING
BN14 8SA
United Kingdom
Telephone:
+44 (01903) 844700
Website:
https://www.allergytherapeutics.com/

Important dates

Future events
AGM 16 December 2024 16/12/24
Past events
Final results 06 November 2024 06/11/24
Trading Announcement 22 July 2024 22/07/24
Interim results 27 March 2024 27/03/24
AGM 08 March 2024 08/03/24
Trading Announcement 14 February 2024 14/02/24
Annual report 30 January 2024 30/01/24

General stock information

EPIC:
AGY
ISIN:
GB00B02LCQ05
Market cap:
£243.09 million
Shares in issue:
4.77 billion
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Manuel Llobet
    Chief Executive Officer, Executive Director
  • Shaun Furlong
    Chief Financial Officer, Executive Director
  • Karley Cheesman
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.